

Statement of Advice:

nilotinib 150mg and 200mg hard capsules (Tasigna®) SMC No 1325/18 **Novartis Pharmaceuticals UK Ltd**

9 February 2018

ADVICE: in the absence of a submission from the holder of the marketing authorisation

nilotinib (Tasigna®) is not recommended for use within NHS Scotland.

Indication under review:

- paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase
- paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman
Scottish Medicines Consortium